Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ALDXAldeyra Therapeutics, Inc.

Nasdaq · CIK 0001341235
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts311

Identity from submissions API

NameAldeyra Therapeutics, Inc.
CIK0001341235
TickersALDX
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN000000000
LEI—
Fiscal year end1231
State of incorporationDE DE
Phone781-761-4904
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • Aldexa Therapeutics, Inc. (2013-01-03T05:00:00.000Z → 2014-03-04T05:00:00.000Z)
  • Neuron Systems Inc (2005-10-06T04:00:00.000Z → 2008-08-01T04:00:00.000Z)
Business address
23 BRADFORD STREET
SUITE 1
CONCORD
MA
01742
MA
Mailing address
23 BRADFORD STREET
SUITE 1
CONCORD
MA
01742
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

654 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-17 8-K 8-K 3.01 0001193125-26-465667 001-36332 261566995 34 173410 1 1
2026-11-16 4 4 0001193125-26-463942 4667
2026-11-13 4 4 0001193125-26-460801 4730
2026-11-13 4 4 0001193125-26-460743 5328
2026-11-12 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001167557-26-000229 005-88182 261544827 34 9108
2026-11-09 8-K 8-K 8.01 0001193125-26-453537 001-36332 261535796 34 175915 1 1
2026-11-06 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0000312069-26-000249 005-88182 261531256 34 6363
2026-11-05 10-Q 10-Q 0001193125-26-449742 001-36332 261527080 34 7705526 1 1
2026-09-29 8-K 8-K 7.01,8.01,9.01 0001193125-26-405954 001-36332 261419109 34 8223803 1 1
2026-08-12 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0001167557-26-000132 005-88182 261265886 34 8952
2026-08-06 10-Q 10-Q 0001341235-26-000010 001-36332 261248731 34 7250198 1 1
2026-07-30 8-K 8-K 1.01,9.01 0001193125-26-326337 001-36332 261224376 34 20078775 1 1
2026-07-27 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0002012383-26-002166 005-88182 261206037 34 10981
2026-07-15 8-K 8-K 8.01 0001193125-26-304880 001-36332 261177866 34 164138 1 1
2026-06-11 4 4 0001193125-26-267634 7956
2026-06-11 4 4 0001193125-26-267629 10382
2026-06-11 4 4 0001193125-26-267623 10301
2026-06-11 4 4 0001193125-26-267611 7970
2026-06-11 4 4 0001193125-26-267605 7929
2026-06-11 4 4 0001193125-26-267600 10236
2026-06-11 4 4 0001193125-26-267587 7835
2026-06-11 3 3 0001193125-26-267553 3267
2026-06-10 8-K 8-K 5.02,5.07,7.01,9.01 0001193125-26-264514 001-36332 261077711 34 275650 1 1
2026-06-05 4 4 0001193125-26-259637 5263
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001193125-26-226558 005-88182 26986544 34 10342
2026-05-07 10-Q 10-Q 0001341235-26-000006 001-36332 26952973 34 7118049 1 1
2026-05-01 8-K 8-K 7.01,9.01 0001193125-26-199157 001-36332 26928960 34 15690233 1 1
2026-04-27 ARS ARS 0001193125-26-182133 001-36332 26901280 34 1022283
2026-04-27 DEFA14A DEFA14A 0001193125-26-182118 001-36332 26901170 34 949433
2026-04-27 DEF 14A DEF 14A 0001193125-26-182099 001-36332 26900990 34 2818026 1 1
2026-04-20 8-K 8-K 5.02 0001193125-26-164198 001-36332 26875808 34 165808 1 1
2026-04-01 8-K 8-K 8.01 0001193125-26-137984 001-36332 26828618 34 165008 1 1
2026-03-31 4 4 0001193125-26-134631 8206
2026-03-26 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000102909-26-000589 005-88182 26797581 34 7386
2026-03-20 4 4 0001193125-26-117675 4712
2026-03-19 4 4 0001193125-26-116247 4669
2026-03-17 8-K 8-K 7.01,8.01,9.01 0001193125-26-109511 001-36332 26759221 34 223756 1 1
2026-02-27 S-8 S-8 0001193125-26-083135 333-293882 26701589 33 207413 1 1
2026-02-27 10-K 10-K 0001193125-26-083012 001-36332 26701082 34 11993980 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-26-054525 005-88182 26640556 34 10936
2025-12-31 8-K 8-K 5.02 0001193125-25-338394 001-36332 251617928 34 137321 1 1
2025-12-16 8-K 8-K 7.01,8.01,9.01 0001193125-25-319638 001-36332 251573017 34 212966 1 1
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001193125-25-282830 005-88182 251485387 34 10937
2025-11-13 8-K 8-K 7.01,8.01,9.01 0001193125-25-278804 001-36332 251475328 34 14927578 1 1
2025-11-05 10-Q 10-Q 0001193125-25-266989 001-36332 251454252 34 8156312 1 1
2025-10-28 8-K 8-K 8.01,9.01 0001193125-25-252200 001-36332 251421241 34 486798 1 1
2025-08-19 8-K 8-K 9.01 0000950170-25-109932 001-36332 251229624 34 275635 1 1
2025-08-15 4 4 0000950170-25-109391 4662
2025-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-108920 005-88182 251219618 34 10832
2025-08-13 4 4 0000950170-25-108210 5555
2025-08-12 144 xsl144X01/primary_doc.xml 0001836354-25-000003 001-36332 251208242 33 4448
2025-08-07 10-Q 10-Q 0000950170-25-104971 001-36332 251193803 34 8370043 1 1
2025-07-17 8-K CURRENT REPORT 8.01,9.01 0001213900-25-064869 001-36332 251128797 34 217203 1 1
2025-06-26 8-K CURRENT REPORT 7.01,8.01,9.01 0001213900-25-058035 001-36332 251075035 34 232427 1 1
2025-06-17 8-K FORM 8-K 8.01,9.01 0001213900-25-054949 001-36332 251051805 34 218991 1 1
2025-06-12 4 4 0000950170-25-085489 7761
2025-06-12 4 4 0000950170-25-085475 7821
2025-06-12 4 4 0000950170-25-085454 10102
2025-06-12 4 4 0000950170-25-085445 10101
2025-06-12 4 4 0000950170-25-085441 10248
2025-06-12 4 4 0000950170-25-085419 10167
2025-06-11 8-K 8-K 5.07 0000950170-25-084820 001-36332 251039876 34 205884 1 1
2025-05-14 10-Q 10-Q 0000950170-25-071602 001-36332 25947046 34 8056075 1 1
2025-05-06 8-K 8-K 7.01,8.01,9.01 0001193125-25-113275 001-36332 25915177 34 1898202 1 1
2025-04-25 ARS ARS 0001193125-25-096939 001-36332 25874554 34 10917119
2025-04-25 DEFA14A DEFA14A 0001193125-25-096925 001-36332 25874507 34 713323
2025-04-25 DEF 14A DEF 14A 0001193125-25-096899 001-36332 25874384 34 2911499 1 1
2025-04-18 4 4 0000950170-25-055900 5381
2025-04-18 3 3 0000950170-25-055877 3126
2025-04-17 8-K CURRENT REPORT 5.02,9.01 0001213900-25-032947 001-36332 25847189 34 234945 1 1
2025-04-07 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-051722 005-88182 25819310 34 10909
2025-04-07 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-007163 9412
2025-04-03 8-K 8-K 7.01,8.01,9.01 0001193125-25-072424 001-36332 25810380 34 5512251 1 1
2025-03-28 10-K/A 10-K/A 0000950170-25-046946 001-36332 25787777 34 300817 1 1
2025-03-06 4 4 0000950170-25-034674 5453
2025-03-06 4 4 0000950170-25-034648 5452
2025-02-28 S-8 S-8 0001193125-25-042772 333-285460 25691910 33 83772
2025-02-28 10-K 10-K 0000950170-25-030102 001-36332 25691076 34 13430322 1 1
2024-11-18 8-K CURRENT REPORT 1.01,8.01,9.01 0001213900-24-099333 001-36332 241469739 34 238915 1 1
2024-11-14 SC 13G/A SC 13G/A 0001193125-24-258735 005-88182 241463739 34 60202
2024-11-07 10-Q 10-Q 0000950170-24-123248 001-36332 241435402 34 7489439 1 1
2024-10-21 4 4 0000950170-24-116048 6315
2024-10-03 8-K CURRENT REPORT 8.01,9.01 0001213900-24-084844 001-36332 241349884 34 228401 1 1
2024-10-02 8-K 8-K 1.01,2.03,9.01 0001193125-24-231158 001-36332 241347403 34 196054 1 1
2024-09-10 3 3 0000950170-24-105145 3204
2024-09-03 8-K 8-K 5.02 0001193125-24-211645 001-36332 241272303 34 149156 1 1
2024-08-14 4 4 0000950170-24-097071 5419
2024-08-14 4 4 0000950170-24-097070 5665
2024-08-12 144 xsl144X01/primary_doc.xml 0001928391-24-000002 001-36332 241198160 33 4520
2024-08-12 144 xsl144X01/primary_doc.xml 0001928391-24-000001 001-36332 241198119 33 4491
2024-08-08 8-K CURRENT REPORT 7.01,8.01,9.01 0001213900-24-066327 001-36332 241185984 34 3688347 1 1
2024-08-01 424B5 424B5 0001193125-24-191601 333-277753 241167663 33 400236
2024-08-01 8-K 8-K 1.01,9.01 0001193125-24-191518 001-36332 241166774 34 453958 1 1
2024-08-01 10-Q 10-Q 0000950170-24-089238 001-36332 241166475 34 8789928 1 1
2024-06-20 8-K CURRENT REPORT 8.01,9.01 0001213900-24-054003 001-36332 241054030 34 4799407 1 1
2024-06-13 8-K CURRENT REPORT 7.01,9.01 0001213900-24-052234 001-36332 241039998 34 219528 1 1
2024-06-07 8-K 8-K 5.07 0001193125-24-157328 001-36332 241029379 34 154204 1 1
2024-06-06 4 4 0000950170-24-069900 10252
2024-06-06 4 4 0000950170-24-069890 10105
2024-06-06 4 4 0000950170-24-069888 7766
2024-06-06 4 4 0000950170-24-069887 7826
2024-06-06 4 4 0000950170-24-069885 10106
2024-06-06 4 4 0000950170-24-069874 10171
2024-05-02 10-Q 10-Q 0000950170-24-052056 001-36332 24908053 34 6433735 1 1
2024-04-25 8-K CURRENT REPORT 7.01,8.01,9.01 0001213900-24-035953 001-36332 24872839 34 20926006 1 1
2024-04-24 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-24 16:00:00 9999999995-24-001104 333-277753 24872631 33 1965
2024-04-22 CORRESP filename1.htm 0001193125-24-104917 7317
2024-04-22 ARS ARS 0001193125-24-104887 001-36332 24861416 34 1086949
2024-04-22 DEFA14A DEFA14A 0001193125-24-104866 001-36332 24861346 34 787246
2024-04-22 DEF 14A DEF 14A 0001193125-24-104862 001-36332 24861327 34 1053775
2024-04-17 4/A 4/A 0000950170-24-045113 6010
2024-04-17 4/A 4/A 0000950170-24-045108 6118
2024-04-08 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-008171 11362
2024-04-03 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-007959 13348
2024-03-28 8-K CURRENT REPORT 7.01,9.01 0001213900-24-026871 001-36332 24793445 34 233900 1 1
2024-03-13 UPLOAD filename1.pdf 0000000000-24-002751 333-277753 40512
2024-03-12 4 4 0000950170-24-030314 7748
2024-03-12 4 4 0000950170-24-030311 10766
2024-03-12 4 4 0000950170-24-030309 9549
2024-03-12 144 xsl144X01/primary_doc.xml 0001950047-24-002180 001-36332 24742026 33 9223
2024-03-11 144 xsl144X01/primary_doc.xml 0001836354-24-000002 001-36332 24740021 33 4519
2024-03-11 144 xsl144X01/primary_doc.xml 0001836354-24-000001 001-36332 24739958 33 4443
2024-03-11 144 xsl144X01/primary_doc.xml 0001972362-24-000397 001-36332 24739722 33 4456
2024-03-07 S-3 S-3 0001193125-24-062285 333-277753 24730975 33 330893
2024-03-07 S-8 S-8 0001193125-24-062277 333-277752 24730907 33 66243
2024-03-07 S-8 POS S-8 POS 0001193125-24-062265 333-275315 24730790 33 30164
2024-03-07 10-K 10-K 0000950170-24-027933 001-36332 24730085 34 11369314 1 1
2024-02-14 SC 13G/A SC 13G/A 0001193125-24-036469 005-88182 24639831 34 59974
2024-02-13 SC 13G SCHEDULE 13G 0001104659-24-020218 005-88182 24627311 34 13237
2024-02-13 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,9.01 0001157523-24-000230 001-36332 24625505 34 4437372 1 1
2024-01-29 SC 13G us01438t1060_012924.txt 0001086364-24-005555 005-88182 24574886 34 13558
2024-01-04 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-24-000014 001-36332 24509740 34 198397 1 1
2023-12-21 8-K 8-K 8.01 0001193125-23-301185 001-36332 231505357 34 142632 1 1
2023-12-19 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-23-001841 001-36332 231495614 34 4122520 1 1
2023-11-28 8-K 8-K 7.01,8.01,9.01 0001193125-23-283679 001-36332 231441889 34 3997323 1 1
2023-11-03 S-8 S-8 0001193125-23-270467 333-275315 231377028 33 120043
2023-11-03 10-Q 10-Q 0000950170-23-058829 001-36332 231376386 34 7498235 1 1
2023-11-01 8-K 8-K 1.01 0001193125-23-267697 001-36332 231366542 34 160989 1 1
2023-10-19 SC 13G/A SC 13G/A 0001193125-23-258680 005-88182 231333029 34 59873
2023-10-18 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-23-019546 11185
2023-10-16 8-K 8-K 8.01 0001193125-23-256532 001-36332 231326240 34 152914 1 1
2023-10-04 SC 13G SC 13G 0001104659-23-106782 005-88182 231307756 34 83759
2023-09-11 4 4 0000950170-23-047530 15034
2023-09-11 4 4 0000950170-23-047497 6657
2023-08-24 4 4 0000950170-23-044379 6567
2023-08-03 10-Q 10-Q 0000950170-23-037934 001-36332 231139798 34 8163266 1 1
2023-07-05 4 4 0000950170-23-031789 10029
2023-07-05 4 4 0000950170-23-031788 10098
2023-07-05 4 4 0000950170-23-031786 7747
2023-07-05 4 4 0000950170-23-031781 10024
2023-07-05 4 4 0000950170-23-031778 10148
2023-07-05 4 4 0000950170-23-031775 7681
2023-07-03 8-K 8-K 5.07 0001193125-23-181344 001-36332 231065350 34 158451 1 1
2023-06-29 4 FORM 4 SUBMISSION 0000899243-23-016709 6958
2023-06-29 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-23-001047 001-36332 231054267 34 4010777 1 1
2023-06-27 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-23-001035 001-36332 231043963 34 3092354 1 1
2023-06-21 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-23-001018 001-36332 231030204 34 193047 1 1
2023-06-15 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-23-000973 001-36332 231015935 34 4193513 1 1
2023-05-24 ARS ARS 0001193125-23-151969 001-36332 23949992 34 3173499
2023-05-23 DEF 14A DEF 14A 0001193125-23-151833 001-36332 23949219 34 1272160
2023-05-04 10-Q 10-Q 0000950170-23-017827 001-36332 23888564 34 6945510 1 1
2023-05-04 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-23-000722 001-36332 23886397 34 295275 1 1
2023-04-28 10-K/A 10-K/A 0001193125-23-126947 001-36332 23866236 34 620771 1 1
2023-03-10 8-K 8-K 7.01 0001193125-23-067701 001-36332 23724438 34 141936 1 1
2023-03-09 S-8 S-8 0001193125-23-066127 333-270401 23719997 33 60190
2023-03-09 10-K 10-K 0000950170-23-006998 001-36332 23719667 34 13034419 1 1
2023-03-09 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-23-000419 001-36332 23718144 34 302530 1 1
2023-03-02 4 FORM 4 SUBMISSION 0000899243-23-006748 5569
2023-03-02 4 FORM 4 SUBMISSION 0000899243-23-006746 5615
2023-03-02 4 FORM 4 SUBMISSION 0000899243-23-006742 7545
2023-03-02 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-23-000387 001-36332 23696386 34 199698 1 1
2023-02-14 SC 13G/A SC 13G/A 0001193125-23-038732 005-88182 23627249 34 64761
2023-02-07 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-23-000181 001-36332 23592754 34 199656 1 1
2023-02-03 SC 13G/A Aldeyra_Therapeutics_Inc.txt 0000093751-23-000131 005-88182 23584402 34 8472
2022-12-27 8-K ALDEYRA THERAPEUTICS, INC. 8-K 1.01,2.03,8.01,9.01 0001157523-22-001788 001-36332 221486786 34 263207 1 1
2022-12-21 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-001777 001-36332 221476483 34 192715 1 1
2022-12-01 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-001698 001-36332 221437398 34 192511 1 1
2022-11-29 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-001684 001-36332 221428370 34 192063 1 1
2022-11-10 10-Q 10-Q 0000950170-22-024434 001-36332 221376937 34 7630886 1 1
2022-11-10 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-22-001587 001-36332 221374890 34 342702 1 1
2022-10-06 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-22-001289 001-36332 221297089 34 3271825 1 1
2022-09-14 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-001225 001-36332 221242102 34 193864 1 1
2022-08-11 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017733 11172
2022-08-10 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017623 9190
2022-08-09 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017559 9191
2022-08-08 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017481 9190
2022-08-05 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017393 9191
2022-08-05 10-Q 10-Q 0000950170-22-015115 001-36332 221140806 34 7310454 1 1
2022-08-05 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-22-001059 001-36332 221138571 34 325531 1 1
2022-08-04 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017281 9193
2022-08-03 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017202 9191
2022-08-02 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-017083 9195
2022-08-01 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-016987 9194
2022-07-19 4 FORM 4 SUBMISSION 0000899243-22-026346 6138
2022-07-19 4 FORM 4 SUBMISSION 0000899243-22-026345 5171
2022-07-19 4 FORM 4 SUBMISSION 0000899243-22-026344 9059
2022-07-12 8-K ALDEYRA THERAPEUTICS, INC. 8-K 7.01,8.01,9.01 0001157523-22-000837 001-36332 221078206 34 4286422 1 1
2022-07-08 SC 13G us01438t1060_070822.txt 0000834237-22-010241 005-88182 221075009 34 12343
2022-06-27 4 FORM 4 SUBMISSION 0000899243-22-024133 5195
2022-06-27 4 FORM 4 SUBMISSION 0000899243-22-024132 5290
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021638 10542
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021637 8103
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021634 10608
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021632 10543
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021633 10673
2022-06-09 4 FORM 4 SUBMISSION 0000899243-22-021626 8043
2022-06-08 8-K ALDEYRA THERAPEUTICS, INC. 8-K 5.07,7.01,8.01,9.01 0001157523-22-000745 001-36332 221002578 34 2806315 1 1
2022-05-24 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-000678 001-36332 22953976 34 189148 1 1
2022-05-18 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-22-000653 001-36332 22937107 34 198266 1 1
2022-05-13 3 FORM 3 SUBMISSION 0000899243-22-018011 10785
2022-05-05 10-Q 10-Q 0000950170-22-007890 001-36332 22897112 34 6690767 1 1
2022-05-05 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-22-000561 001-36332 22894014 34 302147 1 1
2022-04-28 8-K ALDEYRA THERAPEUTICS, INC. 8-K 5.02,9.01 0001157523-22-000502 001-36332 22866663 34 184146 1 1
2022-04-25 DEFA14A DEFA14A 0001193125-22-117594 001-36332 22849947 34 936298
2022-04-25 DEF 14A DEF 14A 0001193125-22-117585 001-36332 22849925 34 1052050
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013176 10174
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013174 7736
2022-04-01 4 FORM 4 SUBMISSION 0000899243-22-013173 8675
2022-03-29 8-K 8-K 7.01,8.01,9.01 0001193125-22-087464 001-36332 22777485 34 21443944 1 1
2022-03-17 S-8 S-8 0001193125-22-078435 333-263660 22749793 33 57960
2022-03-17 10-K 10-K 0000950170-22-004111 001-36332 22749708 34 13696143 1 1
2022-03-17 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-22-000341 001-36332 22746700 34 347130 1 1
2022-02-14 SC 13G/A SC 13G/A 0001193125-22-041509 005-88182 22630797 34 70529
2022-02-09 SC 13G ALDEYRA_THERAPEUTICS_INC.txt 0000093751-22-000049 005-88182 22607965 34 8551
2022-02-04 SC 13G us01438t1060_020422.txt 0000834237-22-007296 005-88182 22593563 34 13301
2022-01-04 SC 13G/A SCHEDULE 13G/A 0000904454-22-000002 005-88182 22504344 34 34892
2021-12-21 8-K 8-K 7.01,8.01,9.01 0001193125-21-363014 001-36332 211506823 34 4321849 1 1
2021-11-09 8-K ALDEYRA THERAPEUTICS, INC. 8-K 8.01,9.01 0001157523-21-001374 001-36332 211389969 34 190969 1 1
2021-11-02 8-K 8-K 8.01,9.01 0001193125-21-316254 001-36332 211369350 34 175671 1 1
2021-10-28 10-Q 10-Q 0000950170-21-002456 001-36332 211358192 34 6611657 1 1
2021-10-28 8-K ALDEYRA THERAPEUTICS, INC. 8-K 2.02,8.01,9.01 0001157523-21-001271 001-36332 211355014 34 323903 1 1
2021-08-05 10-Q 10-Q 0000950170-21-000925 001-36332 211148098 34 6335823 1 1
2021-08-05 8-K 8-K 2.02,8.01,9.01 0001193125-21-236970 001-36332 211146297 34 239295 1 1
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023013 10670
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023012 10608
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023011 8102
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023010 10542
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023009 8042
2021-06-10 4 FORM 4 SUBMISSION 0000899243-21-023007 10540
2021-06-09 8-K 8-K 5.07 0001193125-21-186792 001-36332 211005495 34 155343 1 1
2021-05-06 10-Q 10-Q 0001564590-21-024943 001-36332 21897710 34 6083565 1 1
2021-05-06 8-K 8-K 2.02,8.01,9.01 0001193125-21-152486 001-36332 21895779 34 238082 1 1
2021-05-04 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-004109 8738
2021-04-29 424B5 424B5 0001193125-21-140810 333-254175 21872024 33 490100
2021-04-29 8-K 8-K 1.01,8.01,9.01 0001193125-21-140533 001-36332 21871057 34 519402 1 1
2021-04-27 424B5 424B5 0001193125-21-134419 333-254175 21859774 33 490072
2021-04-27 8-K 8-K 7.01,8.01,9.01 0001193125-21-132903 001-36332 21855984 34 6080243 1 1
2021-04-21 8-K 8-K 1.01,2.03,9.01 0001193125-21-124890 001-36332 21842038 34 203913 1 1
2021-04-15 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-04-15 16:00:00 9999999995-21-001448 333-254175 21830010 33 1916
2021-04-14 4 FORM 4 SUBMISSION 0000899243-21-015839 5594
2021-04-14 4 FORM 4 SUBMISSION 0000899243-21-015838 5579
2021-04-14 4 FORM 4 SUBMISSION 0000899243-21-015837 7553
2021-04-14 DEFA14A DEFA14A 0001564590-21-018848 001-36332 21826527 34 245376
2021-04-14 DEF 14A DEF 14A 0001564590-21-018847 001-36332 21826494 34 888370
2021-04-13 CORRESP filename1.htm 0001193125-21-114658 7811
2021-03-17 UPLOAD filename1.pdf 0000000000-21-003224 40423
2021-03-11 S-3 S-3 0001193125-21-077943 333-254175 21734121 33 623816
2021-03-11 S-8 S-8 0001193125-21-077845 333-254144 21733639 33 45502
2021-03-11 10-K 10-K 0001564590-21-012501 001-36332 21733353 34 9751664 1 1
2021-03-11 8-K 8-K 2.02,8.01,9.01 0001193125-21-077046 001-36332 21731865 34 240543 1 1
2021-02-16 SC 13G/A SC 13G/A 0001193125-21-044700 005-88182 21637164 34 64266
2021-02-16 SC 13G/A aldeyra13ga3-021621.htm 0001013594-21-000156 005-88182 21636702 34 68208
2021-02-12 SC 13G/A SC 13G/A 0001193125-21-040123 005-88182 21623014 34 107092
2021-01-25 8-K 8-K 5.02 0001193125-21-016281 001-36332 21549990 34 143943 1 1
2021-01-21 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-000506 8737
2021-01-14 424B5 424B5 0001193125-21-009091 333-226266 21529159 33 919717
2021-01-14 8-K 8-K 1.01,8.01,9.01 0001193125-21-008625 001-36332 21527512 34 516187 1 1
2021-01-13 424B5 424B5 0001193125-21-008136 333-226266 21526169 33 920942
2021-01-11 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-21-000275 14806
2021-01-07 8-K 8-K 7.01,8.01,9.01 0001193125-21-003740 001-36332 21513009 34 7554892 1 1
2020-12-18 3 FORM 3 SUBMISSION 0000899243-20-034529 11872
2020-11-05 10-Q 10-Q 0001564590-20-051290 001-36332 201290378 34 6710068 1 1
2020-11-05 8-K 8-K 2.02,8.01,9.01 0001193125-20-286220 001-36332 201288671 34 250172 1 1
2020-08-06 10-Q 10-Q 0001564590-20-037714 001-36332 201081551 34 6789998 1 1
2020-08-06 8-K 8-K 2.02,8.01,9.01 0001193125-20-211319 001-36332 201079809 34 111882
2020-07-14 8-K 8-K 8.01,9.01 0001193125-20-192321 001-36332 201026366 34 43905
2020-07-13 4 FORM 4 SUBMISSION 0000899243-20-019004 8950
2020-07-13 SC 13G/A SC 13G/A 0001193125-20-191905 005-88182 201025505 34 64471
2020-07-10 SC 13G/A us01438t1060_071020.txt 0000834237-20-010003 005-88182 201022201 34 12315
2020-07-07 8-K 8-K 8.01,9.01 0001193125-20-188425 001-36332 201015276 34 45762
2020-06-12 8-K 8-K 5.07 0001193125-20-167714 001-36332 20960456 34 33699
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016185 10523
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016183 5631
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016182 10669
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016181 10541
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016180 8042
2020-06-11 4 FORM 4 SUBMISSION 0000899243-20-016177 8132
2020-06-11 4 PRIMARY DOCUMENT 0000904454-20-000398 10306
2020-06-04 8-K 8-K 8.01,9.01 0001193125-20-160151 001-36332 20941933 34 51668
2020-05-20 8-K 8-K 7.01,8.01,9.01 0001193125-20-146738 001-36332 20895707 34 7393253
2020-05-07 10-Q 10-Q 0001564590-20-022912 001-36332 20856903 34 5596788 1
2020-05-07 8-K 8-K 2.02,8.01,9.01 0001193125-20-135600 001-36332 20854569 34 65171
2020-05-01 8-K 8-K 5.03,9.01 0001193125-20-131009 001-36332 20841210 34 126913
2020-04-27 DEFA14A DEFA14A 0001564590-20-018879 001-36332 20821248 34 461922
2020-04-27 DEF 14A DEF 14A 0001564590-20-018862 001-36332 20820874 34 1261782
2020-04-14 8-K 8-K 8.01,9.01 0001193125-20-105860 001-36332 20790113 34 42566
2020-03-17 4 FORM 4 SUBMISSION 0000899243-20-008616 4791
2020-03-12 S-8 S-8 0001193125-20-071672 333-237129 20709501 33 48137
2020-03-12 10-K 10-K 0001564590-20-010493 001-36332 20709224 34 8492369 1
2020-03-12 8-K 8-K 2.02,5.02,8.01,9.01 0001193125-20-070920 001-36332 20707155 34 114537
2020-03-06 4/A FORM 4/A SUBMISSION 0000899243-20-007448 7790
2020-03-06 4/A FORM 4/A SUBMISSION 0000899243-20-007447 8000
2020-03-04 4 FORM 4 SUBMISSION 0000899243-20-007067 7566
2020-03-04 4 FORM 4 SUBMISSION 0000899243-20-007064 7776
2020-03-04 4 FORM 4 SUBMISSION 0000899243-20-007060 10173
2020-02-25 SC 13G SC 13G 0001193125-20-047397 005-88182 20647748 34 133068
2020-02-24 8-K 8-K 8.01,9.01 0001193125-20-045535 001-36332 20642127 34 51290
2020-02-14 SC 13G/A SC 13G/A 0001193125-20-038085 005-88182 20619046 34 66104
2020-02-13 SC 13G/A DECEMBER 31, 2019 0001013594-20-000132 005-88182 20607471 34 85215
2020-02-12 SC 13G/A ALDEYRA THERAPEUTICS, INC. 0000902664-20-000962 005-88182 20604371 34 103835
2020-02-07 SC 13G/A filing.txt 0000315066-20-000826 005-88182 20585460 34 8571
2020-02-07 SC 13G us01438t1060_020620.txt 0000834237-20-008145 005-88182 20584789 34 13258
2020-01-15 4 FORM 4 SUBMISSION 0000899243-20-001261 5503
2020-01-15 3 FORM 3 SUBMISSION 0000899243-20-001258 3118
2020-01-14 8-K 8-K 5.02,9.01 0001193125-20-006782 001-36332 20525013 34 40247
2020-01-10 SC 13G/A SCHEDULE 13G-A FOR ALDEYRA THERAPEUTICS, INC. BY DOMAIN PARTNERS VI, L.P. 0000904454-20-000020 005-88182 20519108 34 33850
2019-12-18 4 FORM 4 SUBMISSION 0000899243-19-029509 4730
2019-12-03 8-K 8-K 7.01,8.01,9.01 0001193125-19-304808 001-36332 191264651 34 8899913
2019-11-07 10-Q 10-Q 0001564590-19-041846 001-36332 191201102 34 5627951 1
2019-11-07 8-K 8-K 2.02,8.01,9.01 0001193125-19-286617 001-36332 191198125 34 104853
2019-10-31 8-K 8-K 7.01,8.01,9.01 0001193125-19-279627 001-36332 191182119 34 6066824
2019-10-02 4 FORM 4 SUBMISSION 0000899243-19-024582 5488
2019-09-27 SC 13G ALDEYRA THERAPEUTICS, INC. 0000902664-19-003845 005-88182 191120605 34 107360
2019-09-25 4 FORM 4 SUBMISSION 0000899243-19-024225 5488
2019-09-24 8-K 8-K 8.01,9.01 0001193125-19-252836 001-36332 191109220 34 38552
2019-09-20 4 FORM 4 SUBMISSION 0000899243-19-023982 5281
2019-09-19 4 FORM 4 SUBMISSION 0000899243-19-023923 4636
2019-09-17 4/A FORM 4/A SUBMISSION 0000899243-19-023735 7044
2019-09-17 4 FORM 4 SUBMISSION 0000899243-19-023719 4790
2019-09-17 4 FORM 4 SUBMISSION 0000899243-19-023718 6252
2019-09-16 4 FORM 4 SUBMISSION 0000899243-19-023628 5195
2019-09-13 4 FORM 4 SUBMISSION 0000899243-19-023539 7416
2019-09-11 4 FORM 4 SUBMISSION 0000899243-19-023317 7545
2019-09-11 4 FORM 4 SUBMISSION 0000899243-19-023315 7416
2019-09-10 4 FORM 4 SUBMISSION 0000899243-19-023265 5426
2019-09-09 4 FORM 4 SUBMISSION 0000899243-19-023129 4934
2019-09-09 4 FORM 4 SUBMISSION 0000899243-19-023128 4943
2019-09-03 8-K 8-K 8.01 0001193125-19-235793 001-36332 191070837 34 19339
2019-08-09 10-Q 10-Q 0001564590-19-031031 001-36332 191011351 34 5326238 1
2019-08-08 8-K 8-K 2.02,8.01,9.01 0001193125-19-216016 001-36332 191007448 34 102017
2019-06-25 8-K 8-K 7.01,8.01,9.01 0001193125-19-180730 001-36332 19916930 34 4167287
2019-06-06 4 FORM 4 SUBMISSION 0000899243-19-015824 10550
2019-06-06 4 FORM 4 SUBMISSION 0000899243-19-015822 8150
2019-06-06 4 FORM 4 SUBMISSION 0000899243-19-015821 10693
2019-06-06 4 FORM 4 SUBMISSION 0000899243-19-015820 10565
2019-06-06 4 FORM 4 SUBMISSION 0000899243-19-015819 8060
2019-06-06 4 PRIMARY DOCUMENT 0000904454-19-000466 10306
2019-06-06 8-K 8-K 5.07,7.01,9.01 0001193125-19-166628 001-36332 19881483 34 15247229
2019-05-10 10-Q 10-Q 0001564590-19-018542 001-36332 19815025 34 4860514 1
2019-05-09 8-K 8-K 2.02,9.01 0001193125-19-142173 001-36332 19808747 34 90009
2019-04-22 DEFA14A DEFA14A 0001564590-19-012254 001-36332 19759547 34 94300
2019-04-22 DEF 14A DEF 14A 0001564590-19-012248 001-36332 19759491 34 1381480
2019-03-28 4 PRIMARY DOCUMENT 0000904454-19-000337 7240
2019-03-26 8-K 8-K 1.01,2.03,7.01,8.01,9.01 0001193125-19-085920 001-36332 19704114 34 9254481
2019-03-08 S-8 S-8 0001193125-19-069189 333-230161 19669566 33 50138
2019-03-08 10-K 10-K 0001564590-19-006997 001-36332 19669147 34 7143800 1
2019-03-08 8-K 8-K 2.02,9.01 0001193125-19-067948 001-36332 19667593 34 83223
2019-03-07 4 FORM 4 SUBMISSION 0000899243-19-006734 5600
2019-03-07 4 FORM 4 SUBMISSION 0000899243-19-006732 7564
2019-03-07 4 FORM 4 SUBMISSION 0000899243-19-006730 7700
2019-03-07 4 FORM 4 SUBMISSION 0000899243-19-006729 10360
2019-02-28 8-K 8-K 7.01,8.01,9.01 0001193125-19-055552 001-36332 19640416 34 20893401
2019-02-14 SC 13G/A SC 13G/A 0001193125-19-040933 005-88182 19606922 34 68884
2019-02-14 SC 13G/A FEBRUARY 14, 2019 0001013594-19-000164 005-88182 19603049 34 93904
2019-02-13 SC 13G/A SC-13G/A 0001178913-19-000432 005-88182 19598284 34 133745
2019-02-13 SC 13G/A filing.txt 0000315066-19-000826 005-88182 19594484 34 8513
2019-02-11 D xslFormDX01/primary_doc.xml 06b 0001582746-19-000001 021-332606 19586488 33 14716
2019-01-29 8-K 8-K 1.01,2.01,3.02,8.01,9.01 0001193125-19-019770 001-36332 19547157 34 613361
2019-01-22 SC 13G/A SCHEDULE 13G-A FOR ALDEYRA THERAPEUTICS, INC. BY JOHNSON & JOHNSON 0000904454-19-000069 005-88182 19534752 34 59747
2018-12-28 424B5 424B5 0001193125-18-360963 333-226266 181257629 33 912817
2018-12-28 8-K 8-K 1.01,9.01 0001193125-18-360931 001-36332 181257528 34 226339
2018-11-21 8-K 8-K 1.02 0001193125-18-331873 001-36332 181197017 34 15087
2018-11-14 10-Q FORM 10-Q 0001193125-18-326837 001-36332 181185131 34 2974247 1
2018-11-14 8-K 8-K 2.02,9.01 0001193125-18-326140 001-36332 181180453 34 89734
2018-10-04 CT ORDER filename1.pdf 20181004,20181004 9999999997-18-008382 001-36332 181107746 34 14046
2018-09-28 8-K 8-K 1.01,8.01,9.01 0001193125-18-287591 001-36332 181094707 34 276828
2018-09-28 424B5 424B5 0001193125-18-287518 333-226266 181094574 33 748153
2018-09-26 424B5 424(B)(5) 0001193125-18-283947 333-226266 181088076 33 746868
2018-09-26 8-K 8-K 7.01,8.01,9.01 0001193125-18-283160 001-36332 181086872 34 11760282
2018-09-25 8-K 8-K 8.01,9.01 0001193125-18-281789 001-36332 181084717 34 509697
2018-08-09 10-Q FORM 10-Q 0001193125-18-244346 001-36332 181005261 34 2938197 1
2018-08-09 8-K 8-K 2.02,9.01 0001193125-18-243481 001-36332 181003432 34 88837
2018-08-01 4 FORM 4 SUBMISSION 0000899243-18-020988 5738
2018-08-01 3 FORM 3 SUBMISSION 0000899243-18-020978 3166
2018-08-01 3 FORM 3 SUBMISSION 0000899243-18-020972 4528
2018-07-31 8-K 8-K 5.02,9.01 0001193125-18-232408 001-36332 18979499 34 41691
2018-07-27 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2018-07-27 16:30:00 9999999995-18-001924 333-226266 18975974 33 1916
2018-07-26 UPLOAD filename1.pdf 0000000000-18-022951 44921
2018-07-25 CORRESP filename1.htm 0001193125-18-225751 7081
2018-07-20 S-3 S-3 0001193125-18-222562 333-226266 18962746 33 1037175
2018-06-26 8-K 8-K 7.01,8.01,9.01 0001193125-18-203119 001-36332 18918296 34 14501958
2018-06-11 4 PRIMARY DOCUMENT 0000904454-18-000424 10293
2018-06-08 4 FORM 4 SUBMISSION 0000899243-18-015771 10547
2018-06-08 4 FORM 4 SUBMISSION 0000899243-18-015770 10704
2018-06-08 4 FORM 4 SUBMISSION 0000899243-18-015769 8057
2018-06-08 4 FORM 4 SUBMISSION 0000899243-18-015767 8151
2018-06-08 4 FORM 4 SUBMISSION 0000899243-18-015766 10565
2018-06-08 8-K FORM 8-K 5.07 0001193125-18-188147 001-36332 18889901 34 25034
2018-05-15 10-Q FORM 10-Q 0001193125-18-164070 001-36332 18836367 34 2513563 1
2018-05-15 8-K FORM 8-K 2.02,9.01 0001193125-18-163406 001-36332 18833090 34 73128

Latest XBRL company facts

One latest value per concept from companyfacts (311 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 60.36M 2026-11-03 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
dei EntityPublicFloat Entity Public Float USD 231.90M 2025-06-30 2025 FY 10-K 2026-02-27 0001193125-26-083012
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 801,510 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182099
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 848,168 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182099
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 4.29M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182099
ecd PeoTotalCompAmt PeoTotalCompAmt USD 4.70M 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182099
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 74.43 2025-01-01 2025-12-31 DEF 14A 2026-04-27 0001193125-26-182099
invest InvestmentWarrantsExercisePrice Investment Warrants, Exercise Price USD 0.125 2015-01-21 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 144,443 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AccrualForTaxesOtherThanIncomeTaxesCurrent Accrual for Taxes Other than Income Taxes, Current USD 106,886 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 908,724 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.56M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AccruedPayrollTaxesCurrent Accrued Payroll Taxes, Current USD 444,786 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 41,985 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD 0 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 62.47M 2015-03-31 2015 Q1 10-Q 2015-05-14 0001193125-15-187962
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 531.78M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Decrease for Tax Withholding Obligation USD 532,951 2023-01-01 2023-12-31 2024 FY 10-K 2025-02-28 0000950170-25-030102
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 3.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 1.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AmortizationOfDebtDiscountPremium Amortization of Debt Discount (Premium) USD 50,368 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 8.95M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AreaOfLand Area of Land sqft 4,067 2026-07-28 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap Assets Assets USD 43.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AssetsCurrent Assets, Current USD 42.92M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AssetsFairValueDisclosure Assets, Fair Value Disclosure USD 38.54M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 103,938 2022-01-01 2022-12-31 2023 Q3 10-Q 2023-11-03 0000950170-23-058829
us-gaap AvailableForSaleSecurities Available-for-sale Securities USD 28.93M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax USD 0 2017-12-31 2017 FY 10-K 2018-03-29 0001193125-18-102077
us-gaap AvailableForSaleSecuritiesCurrent Available-for-sale Securities, Current USD 46.24M 2018-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 29.99M 2022-12-31 2023 Q3 10-Q 2023-11-03 0000950170-23-058829
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 0 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued Business Acquisition, Equity Interest Issued or Issuable, Number of Shares shares 1.16M 2019-01-28 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap Cash Cash USD 33.37M 2022-06-30 2022 Q2 10-Q 2022-08-05 0000950170-22-015115
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 70.04M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD -7.96M 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 44.43M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 40.97M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -29.07M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 10 2018-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights shares 211,528 2015-01-21 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 40,300 2018-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 150.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 60.36M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 60.36M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap CommonStockValue Common Stock, Value, Issued USD 60,357 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -12.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD -38.65M 2014-01-01 2014-06-30 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap ConvertibleNotesPayableCurrent Convertible Notes Payable, Current USD 85,000 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap ConvertiblePreferredStockConvertedToOtherSecurities Convertible Preferred Stock Converted to Other Securities USD -38.65M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 3.64M 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 30,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 170,000 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap DebtConversionConvertedInstrumentSharesIssued1 Debt Conversion, Converted Instrument, Shares Issued shares 21,250 2014-05-08 2014-05-31 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap DebtCurrent Debt, Current USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap DebtInstrumentAnnualPrincipalPayment Debt Instrument, Annual Principal Payment USD 15.00M 2026-04-01 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate pure 0.028 2012-04-12 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap DebtInstrumentCarryingAmount Long-term Debt, Gross USD 14.67M 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022912
us-gaap DebtInstrumentFaceAmount Debt Instrument, Face Amount USD 170,000 2013-10-31 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap DebtInstrumentFairValue Debt Instrument, Fair Value Disclosure USD 29.88M 2022-12-31 2023 Q3 10-Q 2023-11-03 0000950170-23-058829
us-gaap DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage pure 0.06 2013-10-31 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap DebtInstrumentUnamortizedDiscount Debt Instrument, Unamortized Discount USD 133,453 2015-03-31 2015 Q1 10-Q 2015-05-14 0001193125-15-187962
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 0 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredCostsAndOtherAssets Deferred Costs and Other Assets USD 2.51M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredIncomeTaxesAndTaxCredits Deferred Income Taxes and Tax Credits USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-17 0000950170-22-004111
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 16,206 2017-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap DeferredLongTermLiabilityCharges Deferred Long-term Liability Charges USD 6.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 74,335 2021-06-30 2021 Q2 10-Q 2021-08-05 0000950170-21-000925
us-gaap DeferredRevenueCurrent Deferred Revenue, Current USD 6.00M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 78,378 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 130.97M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 1.13M 2025-09-30 2025 Q3 10-Q 2025-11-05 0001193125-25-266989
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 75,365 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal Deferred Tax Assets, Operating Loss Carryforwards, State and Local USD 89.13M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 98,731 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsPropertyPlantAndEquipment Deferred Tax Assets, Property, Plant and Equipment USD 10,173 2018-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 18.19M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.63M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities USD 2.89M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves USD 0 2024-12-31 2024 FY 10-K 2025-02-28 0000950170-25-030102
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 130.89M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs USD 2.21M 2024-12-31 2024 FY 10-K 2025-02-28 0000950170-25-030102
us-gaap DeferredTaxLiabilitiesLeasingArrangements Deferred Tax Liabilities, Leasing Arrangements USD 75,365 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 97 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities Deferred Tax Liabilities, Unrealized Gains on Trading Securities USD 0 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap Depreciation Depreciation USD 292,017 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap DepreciationAmortizationAndAccretionNet Depreciation, Amortization and Accretion, Net USD 202,909 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-10-28 0000950170-21-002456
us-gaap DerivativeGainLossOnDerivativeNet Derivative, Gain (Loss) on Derivative, Net USD -2.33M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap DerivativeLiabilitiesNoncurrent Derivative Liability, Noncurrent USD 253,247 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage Development Stage Enterprise, Deficit Accumulated During Development Stage (Deprecated 2015-01-31) USD 40.92M 2014-03-31 2014 Q1 10-Q 2014-06-11 0001193125-14-233411
us-gaap DividendsPreferredStockCash Dividends, Preferred Stock, Cash USD 15.70M 2012-01-01 2012-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -0.21 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -0.29 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007890
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -0.21 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure 0.214 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent pure -0.398 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0.043 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure 0.011 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0.002 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.021 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure 0 2024-01-01 2024-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure 0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EmployeeBenefitsAndShareBasedCompensation Employee Benefits and Share-based Compensation USD 300,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 839,516 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 7.50M 2021-12-31 2021 FY 10-K 2022-03-17 0000950170-22-004111
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD -2.33M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 5.80M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ImpactOfRestatementOnOpeningRetainedEarningsNetOfTax Impact of Restatement on Opening Retained Earnings, Net of Tax (Deprecated 2020-01-31) USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010493
us-gaap IncomeLossAttributableToParent Income (Loss) Attributable to Parent, before Tax USD 33.85M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD 33.85M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -57.78M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-17 0000950170-22-004111
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2017-01-01 2017-09-30 2017 Q3 10-Q 2017-11-09 0001193125-17-338853
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 7.25M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD 7.11M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 380,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 51,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 837,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -14,018 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -3.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD 4.51M 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-10-28 0000950170-21-002456
us-gaap IncreaseDecreaseInDeferredCharges Increase (Decrease) in Deferred Charges USD 21,998 2015-01-01 2015-09-30 2015 Q3 10-Q 2015-11-13 0001193125-15-376648
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD 50,000 2013-01-01 2013-09-30 2014 Q3 10-Q 2014-11-12 0001193125-14-408602
us-gaap IncreaseDecreaseInInterestPayableNet Increase (Decrease) in Interest Payable, Net USD -2,125 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap IncreaseDecreaseInNotesPayableRelatedParties Increase (Decrease) in Notes Payable, Related Parties USD -2,125 2014-01-01 2014-06-30 2015 Q2 10-Q 2015-08-14 0001193125-15-290681
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 201,616 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap IncrementalCommonSharesAttributableToCallOptionsAndWarrants Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants shares 32,455 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements shares 107,416 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements shares 4,851 2014-01-01 2014-03-31 2014 Q1 10-Q 2014-06-11 0001193125-14-233411
us-gaap InterestExpense Interest Expense USD 976,128 2024-01-01 2024-06-30 2024 Q2 10-Q 2024-08-01 0000950170-24-089238
us-gaap InterestExpenseNonoperating InterestExpenseNonoperating USD 469,140 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap InterestPaid Interest Paid, Including Capitalized Interest, Operating and Investing Activities USD 22,682 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-15 0001193125-18-164070
us-gaap InterestPaidNet Interest Paid, Excluding Capitalized Interest, Operating Activities USD 559,625 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap InterestPayableCurrent Interest Payable, Current USD 1,425 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 1.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 238,532 2018-01-01 2018-12-31 2018 FY 10-K 2019-03-08 0001564590-19-006997
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 513,108 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 98,949 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 115,911 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 151,158 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 147,090 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 57,275 2019-09-30 2019 Q3 10-Q 2019-11-07 0001564590-19-041846
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 54,410 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap Liabilities Liabilities USD 8.16M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 43.38M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LiabilitiesCurrent Liabilities, Current USD 7.88M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LiabilitiesFairValueDisclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LineOfCredit Long-term Line of Credit USD 1.40M 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap LineOfCreditFacilityAmountOutstanding Line of Credit Facility, Amount Outstanding (Deprecated 2014-01-31) USD 500,000 2012-04-12 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap LineOfCreditFacilityAnnualPrincipalPayment Line of Credit Facility, Annual Principal Payment USD 58,160 2016-01-01 2016-09-30 2016 Q3 10-Q 2016-11-14 0001193125-16-767770
us-gaap LineOfCreditFacilityCommitmentFeeAmount Line of Credit Facility, Commitment Fee Amount USD 375,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051290
us-gaap LineOfCreditFacilityCommitmentFeePercentage Line of Credit Facility, Commitment Fee Percentage pure 0.07 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051290
us-gaap LineOfCreditFacilityCurrentBorrowingCapacity Line of Credit Facility, Current Borrowing Capacity USD 1.00M 2013-11-30 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap LineOfCreditFacilityInterestRateAtPeriodEnd Line of Credit Facility, Interest Rate at Period End pure 0.129 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051290
us-gaap LineOfCreditFacilityInterestRateDuringPeriod Line of Credit Facility, Interest Rate During Period pure 0.091 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051290
us-gaap LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity USD 500,000 2012-12-31 2014 Q3 10-Q 2014-11-12 0001193125-14-408602
us-gaap LineOfCreditFacilityPeriodicPaymentPrincipal Line of Credit Facility, Periodic Payment, Principal USD 20,833 2012-01-01 2012-12-31 2014 Q3 10-Q 2014-11-12 0001193125-14-408602
us-gaap LinesOfCreditCurrent Line of Credit, Current USD 279,957 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123248
us-gaap LongTermDebt Long-term Debt USD 15.30M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001341235-26-000006
us-gaap LongTermDebtCurrent Long-term Debt, Current Maturities USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Long-Term Debt, Maturity, Year One USD 15.30M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001341235-26-000006
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Long-Term Debt, Maturity, Year Five USD 6.45M 2018-12-31 2019 Q3 10-Q 2019-11-07 0001564590-19-041846
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Long-Term Debt, Maturity, Year Four USD 6.45M 2019-12-31 2020 Q3 10-Q 2020-11-05 0001564590-20-051290
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Long-Term Debt, Maturity, Year Three USD 6.45M 2020-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Long-Term Debt, Maturity, Year Two USD 15.30M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear Long-Term Debt, Maturity, Remainder of Fiscal Year USD 292,500 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123248
us-gaap LongTermDebtNoncurrent Long-term Debt, Excluding Current Maturities USD 0 2026-03-31 2026 Q1 10-Q 2026-05-07 0001341235-26-000006
us-gaap LongTermLoansPayable Loans Payable, Noncurrent USD 15.00M 2026-03-31 2026 Q1 10-Q 2026-05-07 0001341235-26-000006
us-gaap MarketableSecurities Marketable Securities USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 46.62M 2024-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap MarketableSecuritiesUnrealizedGainLoss Marketable Securities, Unrealized Gain (Loss) USD -100,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap MoneyMarketFundsAtCarryingValue Money Market Funds, at Carrying Value USD 8.64M 2022-06-30 2022 Q2 10-Q 2022-08-05 0000950170-22-015115
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -15.22M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 4.09M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-15 0001193125-18-164070
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD -23,097 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD 4.80M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-15 0001193125-18-164070
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -13.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -7.95M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-15 0001193125-18-164070
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -12.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -4.97M 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-09 0001193125-16-582737
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -4.97M 2016-01-01 2016-03-31 2016 Q1 10-Q 2016-05-09 0001193125-16-582737
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 867,842 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -13.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeaseExpense Operating Lease, Expense USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 458,698 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 178,577 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 280,121 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 445,121 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 465,991 2018-12-31 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 228,320 2018-12-31 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 0 2017-12-31 2017 FY 10-K 2018-03-29 0001193125-18-102077
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 0 2018-12-31 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 237,671 2018-12-31 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 17,000 2014-09-30 2014 Q3 10-Q 2014-11-12 0001193125-14-408602
us-gaap OperatingLeasesRentExpenseNet Operating Leases, Rent Expense, Net USD 5,604 2014-01-01 2014-12-31 2016 FY 10-K 2017-03-30 0001193125-17-104228
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.088 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 48,657 2015-12-31 2016 Q3 10-Q 2016-11-14 0001193125-16-767770
us-gaap OtherAccruedLiabilitiesCurrentAndNoncurrent Other Accrued Liabilities USD 502,232 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OtherAssetsCurrent Other Assets, Current USD 755,545 2025-03-31 2025 Q1 10-Q 2025-05-14 0000950170-25-071602
us-gaap OtherAssetsMiscellaneousCurrent Other Assets, Miscellaneous, Current USD 459,593 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -37,442 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap OtherNonoperatingExpense Other Nonoperating Expense USD 1,987 2013-01-01 2013-09-30 2014 Q3 10-Q 2014-11-12 0001193125-14-408602
us-gaap OtherNonoperatingIncome Other Nonoperating Income USD 250,756 2004-08-13 2014-03-31 2014 Q1 10-Q 2014-06-11 0001193125-14-233411
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-28 0000950170-25-030102
us-gaap PaymentsToAcquireAvailableForSaleSecurities Payments to Acquire Available-for-sale Securities USD 0 2021-01-01 2021-09-30 2021 Q3 10-Q 2021-10-28 0000950170-21-002456
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-07 0000950170-24-027933
us-gaap PreferredStockAccretionOfRedemptionDiscount Preferred Stock, Accretion of Redemption Discount USD 333,082 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap PreferredStockDividendsAndOtherAdjustments Preferred Stock Dividends and Other Adjustments USD 15.66M 2004-08-13 2014-03-31 2014 Q1 10-Q 2014-06-11 0001193125-14-233411
us-gaap PreferredStockDividendsIncomeStatementImpact Preferred Stock Dividends, Income Statement Impact USD 4.05M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 15.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 1.94M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PrepaidInsurance Prepaid Insurance USD 867,907 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 10.00M 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-104228
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-05 0001193125-25-266989
us-gaap ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt USD 14.45M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 1.90M 2015-01-21 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 2.75M 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised USD 9,692 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised USD 194,849 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-07 0001564590-19-041846
us-gaap ProceedsFromLinesOfCredit Proceeds from Lines of Credit USD 1.40M 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap ProceedsFromNotesPayable Proceeds from Notes Payable USD 170,000 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap ProceedsFromRepurchaseOfEquity Proceeds from (Repurchase of) Equity USD 19.50M 2015-05-22 2016 FY 10-K 2017-03-30 0001193125-17-104228
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 71,140 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -12.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 17,991 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap RepaymentsOfLinesOfCredit Repayments of Lines of Credit USD 1.40M 2018-01-01 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010493
us-gaap RepaymentsOfLongTermDebtAndCapitalSecurities Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security USD 15.00M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap RepaymentsOfNotesPayable Repayments of Notes Payable USD 41,667 2013-01-01 2013-06-30 2014 Q2 10-Q 2014-08-07 0001193125-14-300661
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 7.73M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-17 0000950170-22-004111
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -496.62M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 300,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 211,528 2015-01-21 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 9.33 2015-01-21 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap SecuritiesForReverseRepurchaseAgreements Securities for Reverse Repurchase Agreements USD 11.00M 2018-09-30 2018 Q3 10-Q 2018-11-14 0001193125-18-326837
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 1.77M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 604,009 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123248
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 5.41 2024-09-30 2024 Q3 10-Q 2024-11-07 0000950170-24-123248
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate pure 0.89 2016-01-01 2016-12-31 2016 FY 10-K 2017-03-30 0001193125-17-104228
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized shares 871,571 2015-01-01 2015-03-31 2015 Q1 10-Q 2015-05-14 0001193125-15-187962
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 5.53M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 5.4 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 12,997 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 1.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 875,824 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 3.76 2017-01-01 2017-12-31 2017 FY 10-K 2018-03-29 0001193125-18-102077
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 8.89M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 4.39 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 1.40M 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 1.57 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value USD 1.80M 2014-01-01 2014-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 165,162 2019-01-01 2019-06-30 2019 Q2 10-Q 2019-08-09 0001564590-19-031031
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent pure 1 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 3.56 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 5.97 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 4.45 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.77 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap SharePrice Share Price USD/shares 1.23 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 35.22M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD 123.01M 2023-09-30 2023 Q3 10-Q 2023-11-03 0000950170-23-058829
us-gaap StockIssuedDuringPeriodSharesNewIssues Stock Issued During Period, Shares, New Issues shares 444,000 2018-04-01 2018-05-15 2018 Q1 10-Q 2018-05-15 0001193125-18-164070
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 20,009 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 170,000 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 9,692 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 23,324 2022-01-01 2022-03-31 2023 Q1 10-Q 2023-05-04 0000950170-23-017827
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardGross Stock Issued During Period, Value, Restricted Stock Award, Gross USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-04 0000950170-23-017827
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 71,140 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense) USD 400,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap StockOptionPlanExpense Stock or Unit Option Plan Expense USD 340,000 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap TaxCreditCarryforwardAmount Tax Credit Carryforward, Amount USD 2.80M 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap TemporaryEquityAccretionToRedemptionValueAdjustment Temporary Equity, Accretion to Redemption Value, Adjustment USD 333,082 2014-01-01 2014-12-31 2015 FY 10-K 2016-03-30 0001193125-16-523952
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 38.32M 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap UnamortizedDebtIssuanceExpense Unamortized Debt Issuance Expense USD 0 2026-03-31 2026 Q1 10-Q 2026-05-07 0001341235-26-000006
us-gaap UndistributedEarningsAllocatedToParticipatingSecurities Undistributed Earnings Allocated to Participating Securities (Deprecated 2014-01-31) USD 11.35M 2004-08-13 2014-03-31 2014 Q1 10-Q 2014-06-11 0001193125-14-233411
us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic USD 223,442 2014-01-01 2014-03-31 2015 Q1 10-Q 2015-05-14 0001193125-15-187962
us-gaap UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense Unrecognized Tax Benefits, Interest on Income Taxes Expense USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-02-28 0000950170-25-030102
us-gaap USGovernmentSecuritiesAtCarryingValue US Government Securities, at Carrying Value USD 28.93M 2019-12-31 2020 FY 10-K 2021-03-11 0001564590-21-012501
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 9.40M 2025-01-01 2025-12-31 2025 FY 10-K 2026-02-27 0001193125-26-083012
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 178,000 2013-11-30 2017 FY 10-K 2018-03-29 0001193125-18-102077
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 60.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 58.30M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-05 0000950170-22-007890
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 60.33M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742
us-gaap WeightedAverageNumberOfSharesTreasuryStock Weighted Average Number of Shares, Treasury Stock shares 429,663 2013-01-01 2013-12-31 2014 FY 10-K 2015-03-23 0001193125-15-101703
us-gaap WriteOffOfDeferredDebtIssuanceCost Write off of Deferred Debt Issuance Cost USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001193125-26-449742

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →